| scholarly article | Q13442814 |
| P50 | author | Filippo Spreafico | Q37831595 |
| Norbert Graf | Q39739734 | ||
| P2093 | author name string | K. Pritchard-Jones | |
| C. V. Fernandez | |||
| E. A. Mullen | |||
| J. I. Geller | |||
| J. S. Dome | |||
| M. Van den Heuvel-Eibrink | |||
| P2860 | cites work | Risk stratification for wilms tumor: current approach and future directions | Q26863695 |
| Children's Oncology Group's 2013 blueprint for research: renal tumors | Q27000449 | ||
| Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors | Q28280617 | ||
| Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group | Q33182388 | ||
| Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group | Q33237025 | ||
| Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group | Q33375430 | ||
| Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. | Q33717311 | ||
| Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour | Q33772549 | ||
| The role of preoperative chemotherapy in the management of Wilms' tumor. The SIOP studies. International Society of Pediatric Oncology | Q34031404 | ||
| Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours | Q34157777 | ||
| Primary lung metastases in pediatric malignant non-Wilms renal tumors: data from SIOP 93-01/GPOH and SIOP 2001/GPOH. | Q34238064 | ||
| Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. | Q34238246 | ||
| Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations | Q34315279 | ||
| Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group | Q34446746 | ||
| Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors | Q34517703 | ||
| Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study | Q34949192 | ||
| Clinical and biologic significance of nuclear unrest in Wilms tumor | Q35113842 | ||
| The yin and yang of kidney development and Wilms' tumors | Q35173260 | ||
| Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group | Q35185392 | ||
| Multiple mechanisms of MYCN dysregulation in Wilms tumour | Q35740193 | ||
| Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors | Q35746228 | ||
| Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children's Oncology Group | Q36096152 | ||
| Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. | Q36115135 | ||
| Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study | Q36252754 | ||
| The value of surgery in directing therapy for patients with Wilms' tumor with pulmonary disease. A report from the National Wilms' Tumor Study Group (National Wilms' Tumor Study 5). | Q36367207 | ||
| Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor | Q36678146 | ||
| Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. | Q36709112 | ||
| The management of synchronous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group | Q36983667 | ||
| Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups | Q37038669 | ||
| Central pathology review in multicenter trials and studies: lessons from the nephroblastoma trials | Q37400822 | ||
| Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. | Q37437735 | ||
| Treatment of relapsed Wilms tumors: lessons learned. | Q37642795 | ||
| Management of adults with Wilms' tumor: recommendations based on international consensus | Q37909371 | ||
| An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour | Q38041750 | ||
| The Collaborative Wilms Tumour Africa Project; Baseline evaluation of Wilms tumour treatment and outcome in eight institutes in sub-Saharan Africa | Q38281314 | ||
| Gain of 1q is a marker of poor prognosis in Wilms' tumors | Q39349862 | ||
| Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial. | Q39641235 | ||
| Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters | Q40850830 | ||
| Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group | Q40949538 | ||
| Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group | Q41036122 | ||
| Use of chest computed tomography in the staging of pediatric Wilms' tumor: interobserver variability and prognostic significance | Q41524769 | ||
| High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma | Q44245121 | ||
| Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital | Q44978600 | ||
| Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies | Q45030870 | ||
| Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial | Q45089277 | ||
| Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology | Q45760446 | ||
| Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. | Q50601697 | ||
| The contribution of chest CT-scan at diagnosis in children with unilateral Wilms' tumour. Results of the SIOP 2001 study. | Q50622557 | ||
| Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. | Q50729780 | ||
| Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. | Q52534486 | ||
| Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). | Q53077900 | ||
| Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01. | Q53127087 | ||
| Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. | Q53318349 | ||
| The treatment of stages I-IV favorable histology Wilms' tumor. | Q53641282 | ||
| Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. | Q54218094 | ||
| Treatment of Pulmonary Metastases in Children With Stage IV Nephroblastoma With Risk-Based Use of Pulmonary Radiotherapy | Q57339553 | ||
| Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis | Q57339656 | ||
| Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: Experience by the Italian association of pediatric hematology and oncology | Q60628606 | ||
| Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in wilms tumor | Q63722756 | ||
| Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour | Q63722785 | ||
| Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse | Q63722795 | ||
| A third Wilms' tumor locus on chromosome 16q | Q67848748 | ||
| Prognostic factors in nonmetastatic, favorable histology Wilms' tumor. Results of the Third National Wilms' Tumor Study | Q68259951 | ||
| Local control in synchronous bilateral Wilms tumor | Q71843730 | ||
| Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations | Q72161523 | ||
| Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome | Q72373963 | ||
| Chromosome 1q expression profiling and relapse in Wilms' tumour | Q74811895 | ||
| High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study | Q77435847 | ||
| Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group | Q77614518 | ||
| Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital | Q78045349 | ||
| Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies | Q81659961 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | collaboration | Q1145523 |
| nephroblastoma | Q756289 | ||
| P304 | page(s) | 2999-3007 | |
| P577 | publication date | 2015-09-20 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration | |
| P478 | volume | 33 |
| Q91584812 | A three long non-coding RNA signature to improve survival prediction in patients with Wilms' tumor |
| Q89853904 | ALKBH5 gene polymorphisms and Wilms tumor risk in Chinese children: A five-center case-control study |
| Q43100180 | Apparent diffusion coefficient as it relates to histopathology findings in post-chemotherapy nephroblastoma: a feasibility study |
| Q91248929 | Assessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: a population-based registry study |
| Q58795135 | Association between NER Pathway Gene Polymorphisms and Wilms Tumor Risk |
| Q47104294 | Association between long interspersed nuclear element-1 methylation levels and relapse in Wilms tumors |
| Q64100714 | Association of and gene polymorphisms with Wilms tumor risk: a four-center case-control study |
| Q92866879 | Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report |
| Q89221857 | Base Excision Repair Gene Polymorphisms and Wilms Tumor Susceptibility |
| Q58699666 | Bilateral Wilms Tumor: A Surgical Perspective |
| Q58113239 | Biological Drivers of Wilms Tumor Prognosis and Treatment |
| Q36040458 | Biomarkers for Wilms Tumor: A Systematic Review |
| Q90316280 | Challenges and Opportunities for Childhood Cancer Drug Development |
| Q51739895 | Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors. |
| Q38998052 | Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. |
| Q100433819 | Clinically and biologically relevant subgroups of Wilms tumour defined by genomic and epigenomic analyses |
| Q60046199 | Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome |
| Q64100784 | Comparison of 3-Dimensional and Augmented Reality Kidney Models With Conventional Imaging Data in the Preoperative Assessment of Children With Wilms Tumors |
| Q90152273 | Comprehensive Analysis of lncRNA-Mediated ceRNA Crosstalk and Identification of Prognostic Biomarkers in Wilms' Tumor |
| Q64970152 | Delivery of radiation therapy in resource-limited settings: A pilot quality assessment study. |
| Q98953108 | Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines |
| Q38734260 | Factors possibly affecting prognosis in children with Wilms' tumor diagnosed before 24 months of age: A report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Wilms Tumor Working Group. |
| Q92163417 | Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor |
| Q42274969 | Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors |
| Q92703125 | Genes Controlled by DNA Methylation Are Involved in Wilms Tumor Progression |
| Q49569330 | HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients. |
| Q95643669 | HOXB2 and FOXC1 synergistically drive the progression of Wilms tumor |
| Q90168408 | High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation |
| Q90340367 | High-risk blastemal Wilms tumor can be modeled by 3D spheroid cultures in vitro |
| Q48265359 | LINC00473 antagonizes the tumour suppressor miR-195 to mediate the pathogenesis of Wilms tumour via IKKα. |
| Q55399851 | MiR-1180-5p regulates apoptosis of Wilms' tumor by targeting p73. |
| Q64236076 | MicroRNA-539 inhibits the progression of Wilms' Tumor through downregulation of JAG1 and Notch1/3 |
| Q37706888 | Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients |
| Q64970878 | Mutations in microRNA processing genes in Wilms tumors derepress the IGF2 regulator PLAG1. |
| Q89365157 | Optimising surveillance for relapse of Wilms' tumour |
| Q47797328 | Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. |
| Q39015477 | Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials |
| Q48564189 | Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol |
| Q92219613 | Prognostic Factors and Nomograms to Predict Overall and Cancer-Specific Survival for Children with Wilms' Tumor |
| Q92482690 | Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor |
| Q33772198 | Recent advances in the management of Wilms' tumor. |
| Q38630842 | Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group |
| Q95852637 | Results of treatment for patients with multicentric or bilaterally predisposed unilateral Wilms tumor (AREN0534): A report from the Children's Oncology Group |
| Q64262600 | SOX21-AS1 is associated with clinical stage and regulates cell proliferation in nephroblastoma |
| Q37290498 | Senescence Process in Primary Wilms' Tumor Cell Culture Induced by p53 Independent p21 Expression |
| Q38783142 | Silencing of hypoxia inducible factor-1α by RNA interference inhibits growth of SK-NEP-1 Wilms tumour cells in vitro, and suppresses tumourigenesis and angiogenesis in vivo |
| Q111441997 | Single cell derived mRNA signals across human kidney tumors |
| Q56761473 | Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors |
| Q47141863 | TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia |
| Q94652183 | The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global |
| Q38815578 | The Evolving Role of Minimally Invasive Surgery in Pediatric and Adolescent Urologic Oncology |
| Q58556220 | The PI3K/AKT axis modulates AATF activity in Wilms' tumor cells |
| Q100696238 | The SIOP-Renal Tumour Study Group consensus statement on flank target volume delineation for highly conformal radiotherapy |
| Q40289487 | The correlation between LIN28B gene potentially functional variants and Wilms tumor susceptibility in Chinese children. |
| Q91297749 | The genetic changes of Wilms tumour |
| Q49599570 | Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas. |
| Q93121850 | Treatment of Wilms Tumor in Sub-Saharan Africa: Results of the Second French African Pediatric Oncology Group Study |
| Q54336619 | Whole-tumor apparent diffusion coefficient measurements in nephroblastoma: Can it identify blastemal predominance? |
| Q47137911 | Wilms Tumor Treatment Outcomes: Perspectives From a Low-Income Setting |
| Q90272454 | Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases |
| Q91979206 | Wilms tumor in a left pelvic kidney: A case report |
| Q98612813 | miR-30d Induced Apoptosis by Targeting Sox4 to Inhibit the Proliferation, Invasion and Migration of Nephroblastoma |
| Q90352803 | miR-423 rs6505162 C>A polymorphism contributes to decreased Wilms tumor risk |
Search more.